Intellectual Property

Formycon already has a strong intellectual property position based on outstanding know-how and numerous scientific and technological innovations. In the field of biosimilars, innovations can relate, for example, to aspects of manufacturing, the galenic form (formulation), and the medical devices (e.g. pre-filled syringes) used to store and administer the drug. In the case of our innovative COVID-19 drug FYB207, the focus is also on patent protection for the product candidate (active ingredient), the formulation, and the technology platform.

Formycon and its licensing partners currently hold more than 15 patent families across the beforementioned spectrum**. These include patent applications in various stages of the application process as well as granted patents. Thus, intellectual property is an important differentiator and supports the long-term success of our product pipeline.